Answers are grounded in this paper and cite their sources.
T umor lysis syndrome is characterized by a group of metabolic derangements caused by the massive and abrupt release of cellular components into the blood following the rapid lysis of malignant cells. It is observed most frequently in patients with hematologic malignancies such as acute lymphoblastic leukemia (ALL) and Burkitt's lymphoma after the initiation of chemotherapy, although it may also occur in other malignancies, both hematologic and solid tumors. 2] The key to the management of tumor lysis syndrome includes awareness of its causes, identification of high-risk patients, implementation of appropriate prophylactic measures, vigilant monitoring of electrolyte levels in patients undergoing chemotherapy, and initiation of more active treatment measures when necessary.
No takes yet. Share an insight, caveat, or question.
Hochberg et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: